$KPTI
Karyopharm Therapeutics Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024055672 Filed on May 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $42.79M $33.13M
YoY Change 13.86% -14.4%
Cost Of Revenue $1.465M $1.911M
YoY Change 22.7% 41.45%
Gross Profit $41.32M $31.22M
YoY Change 13.57% -16.42%
Gross Profit Margin 96.58% 94.23%
Selling, General & Admin $31.07M $29.55M
YoY Change -9.89% -17.71%
% of Gross Profit 75.19% 94.66%
Research & Development $38.37M $35.43M
YoY Change 21.9% 9.54%
% of Gross Profit 92.86% 113.49%
Depreciation & Amortization $91.00K $85.00K
YoY Change 9.64% -70.69%
% of Gross Profit 0.22% 0.27%
Operating Expenses $70.91M $66.89M
YoY Change 7.5% -3.9%
Operating Profit -$28.12M -$33.76M
YoY Change -4.91% 9.26%
Interest Expense $8.949M $5.884M
YoY Change -402.33% 2.19%
% of Operating Profit
Other Income/Expense, Net $51.98M -$3.532M
YoY Change 173163.33% 11.31%
Pretax Income $23.86M -$37.29M
YoY Change -173.41% 9.45%
Income Tax $67.00K $71.00K
% Of Pretax Income 0.28%
Net Earnings $23.79M -$37.36M
YoY Change -172.91% 9.48%
Net Earnings / Revenue 55.61% -112.79%
Basic Earnings Per Share $0.15 -$0.32
Diluted Earnings Per Share -$0.20 -$0.32
COMMON SHARES
Basic Shares Outstanding 117.7M 115.1M
Diluted Shares Outstanding 154.4M 115.5M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $152.1M $148.6M
YoY Change -35.75% -42.94%
Cash & Equivalents $84.77M $30.63M
Short-Term Investments $67.35M $118.0M
Other Short-Term Assets $14.95M $15.94M
YoY Change -19.93% -16.69%
Inventory $3.476M $2.769M
Prepaid Expenses
Receivables $38.00M $31.08M
Other Receivables $0.00 $0.00
Total Short-Term Assets $208.5M $198.4M
YoY Change -28.43% -37.73%
LONG-TERM ASSETS
Property, Plant & Equipment $628.0K $719.0K
YoY Change -89.64% -15.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.638M $1.638M
YoY Change 323.26% 158.36%
Total Long-Term Assets $5.437M $6.092M
YoY Change -15.69% -16.08%
TOTAL ASSETS
Total Short-Term Assets $208.5M $198.4M
Total Long-Term Assets $5.437M $6.092M
Total Assets $214.0M $204.5M
YoY Change -28.15% -37.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.797M $5.028M
YoY Change 22.3% -44.41%
Accrued Expenses $49.81M $54.85M
YoY Change -9.26% 16.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $57.62M $65.34M
YoY Change -2.22% 6.15%
LONG-TERM LIABILITIES
Long-Term Debt $264.6M $303.6M
YoY Change -12.73% 0.19%
Other Long-Term Liabilities $4.281M $2.582M
YoY Change -38.27% 137.97%
Total Long-Term Liabilities $4.281M $2.582M
YoY Change -98.62% 137.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $57.62M $65.34M
Total Long-Term Liabilities $4.281M $2.582M
Total Liabilities $346.1M $373.4M
YoY Change -6.22% 0.66%
SHAREHOLDERS EQUITY
Retained Earnings -$1.501B -$1.524B
YoY Change 6.37% 10.62%
Common Stock $1.369B $1.356B
YoY Change 2.15% 1.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$132.1M -$169.0M
YoY Change
Total Liabilities & Shareholders Equity $214.0M $204.5M
YoY Change -28.15% -37.24%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income $23.79M -$37.36M
YoY Change -172.91% 9.48%
Depreciation, Depletion And Amortization $91.00K $85.00K
YoY Change 9.64% -70.69%
Cash From Operating Activities -$38.50M -$43.73M
YoY Change 49.81% 131.23%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $195.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $51.26M $22.14M
YoY Change 142.14% -168.34%
Cash From Investing Activities $51.26M $21.94M
YoY Change 142.14% -167.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.97M
YoY Change 4663.49%
NET CHANGE
Cash From Operating Activities -38.50M -43.73M
Cash From Investing Activities 51.26M 21.94M
Cash From Financing Activities 40.97M
Net Change In Cash 53.73M -21.80M
YoY Change -1564.83% -57.54%
FREE CASH FLOW
Cash From Operating Activities -$38.50M -$43.73M
Capital Expenditures $0.00 $195.0K
Free Cash Flow -$38.50M -$43.92M
YoY Change 49.81% 132.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001503802
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-36167
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Karyopharm Therapeutics Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3931704
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
85 Wells Avenue, 2nd Floor
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Newton
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02459
CY2024Q1 dei City Area Code
CityAreaCode
617
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
658-0600
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2024Q1 dei Trading Symbol
TradingSymbol
KPTI
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
117710263
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30628000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52231000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
117950000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
139212000
CY2024Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
31082000
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
26962000
CY2024Q1 us-gaap Inventory Net
InventoryNet
2769000
CY2023Q4 us-gaap Inventory Net
InventoryNet
3043000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
15478000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11813000
CY2024Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
459000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
660000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
198366000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
233921000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
719000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
606000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3735000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4276000
CY2024Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
304000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
301000
CY2024Q1 us-gaap Other Assets
OtherAssets
1334000
CY2023Q4 us-gaap Other Assets
OtherAssets
1334000
CY2024Q1 us-gaap Assets
Assets
204458000
CY2023Q4 us-gaap Assets
Assets
240438000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5028000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3123000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
54851000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
61394000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3425000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3308000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2037000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1654000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
65341000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
69479000
CY2024Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
171127000
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
170919000
CY2024Q1 kpti Deferred Royalty Obligation Noncurrent
DeferredRoyaltyObligationNoncurrent
132479000
CY2023Q4 kpti Deferred Royalty Obligation Noncurrent
DeferredRoyaltyObligationNoncurrent
132479000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1884000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2789000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2582000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
978000
CY2024Q1 us-gaap Liabilities
Liabilities
373413000
CY2023Q4 us-gaap Liabilities
Liabilities
376644000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
116457000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
116457000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
114915000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
114915000
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
12000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1355951000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1350981000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-518000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-161000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1524400000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1487038000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-168955000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-136206000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
204458000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
240438000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33126000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38698000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35425000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32339000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
29549000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35907000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
66885000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
69597000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-33759000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-30899000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2156000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2849000
CY2024Q1 us-gaap Interest Expense
InterestExpense
5884000
CY2023Q1 us-gaap Interest Expense
InterestExpense
5758000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
196000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-264000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3532000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3173000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-37291000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34072000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
71000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
54000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-37362000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-34126000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115454000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115454000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113481000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113481000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-37362000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-34126000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-39000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
33000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-318000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
186000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37719000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33907000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-37362000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-34126000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4970000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5389000
CY2024Q1 us-gaap Depreciation
Depreciation
85000
CY2023Q1 us-gaap Depreciation
Depreciation
290000
CY2024Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
208000
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
201000
CY2024Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
911000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1126000
CY2024Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-4000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4120000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-11886000
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-274000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-397000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3665000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1537000
CY2024Q1 kpti Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-541000
CY2023Q1 kpti Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-462000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1905000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6272000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4862000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-9414000
CY2024Q1 kpti Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-788000
CY2023Q1 kpti Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-682000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43725000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18910000
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
53743000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
27944000
CY2024Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
31608000
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
60332000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
195000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
21940000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-32388000
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-16000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-45000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21801000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-51343000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53192000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
136885000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31391000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85542000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30628000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84062000
CY2024Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
459000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
846000
CY2024Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
304000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
634000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31391000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85542000
CY2024Q1 kpti Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
948000
CY2023Q1 kpti Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
923000
CY2024Q1 us-gaap Payments For Royalties
PaymentsForRoyalties
4103000
CY2023Q1 us-gaap Payments For Royalties
PaymentsForRoyalties
4076000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-136206000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4970000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-39000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-318000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-37362000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-168955000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-16656000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5389000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
33000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
186000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-45174000
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2024Q1 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
553000
CY2023Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
553000
CY2024Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
1589000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1732000
CY2024Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
627000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
758000
CY2024Q1 us-gaap Inventory Net
InventoryNet
2769000
CY2023Q4 us-gaap Inventory Net
InventoryNet
3043000
CY2024Q1 kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
7120000
CY2023Q1 kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
10410000
CY2024Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
132020000
CY2024Q1 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
2800000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
169173000
CY2023Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
2800000
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
118057000
CY2024Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
30000
CY2024Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
137000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
117950000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
139281000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
96000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
165000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
139212000
CY2024Q1 kpti Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Years
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYears
55
CY2023Q4 kpti Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Years
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYears
41
CY2024Q1 kpti Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Other Than Temporary Impairments
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments
0
CY2023Q4 kpti Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Other Than Temporary Impairments
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments
0
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
93500000
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
126000
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
8851000
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
11000
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
102351000
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
137000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
84465000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
152000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
6276000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
13000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
90741000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
165000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4970000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5389000
CY2024Q1 kpti Debt Instrument Convertible Threshold Measurement Period Description
DebtInstrumentConvertibleThresholdMeasurementPeriodDescription
during the five-business day period immediately after any five consecutive trading day period
CY2024Q1 us-gaap Debt Instrument Convertible Threshold Consecutive Trading Days1
DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
5
CY2024Q1 kpti Principal Amount Of Notes Used In Conversion Rate
PrincipalAmountOfNotesUsedInConversionRate
1000
CY2024Q1 kpti Debt Instrument Convertible Threshold Maximum Percentage Of Product Of Last Reported Sale Price Of Common Stock
DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock
0.98
CY2024Q2 kpti Debt Instrument Exchange Amount
DebtInstrumentExchangeAmount
148000
CY2024Q1 kpti Percentage Of Redemption Fee
PercentageOfRedemptionFee
0.03
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0001
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.25
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-055672-index-headers.html Edgar Link pending
0000950170-24-055672-index.html Edgar Link pending
0000950170-24-055672.txt Edgar Link pending
0000950170-24-055672-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img175285707_0.jpg Edgar Link pending
kpti-20240331.htm Edgar Link pending
kpti-20240331.xsd Edgar Link pending
kpti-ex10_1.htm Edgar Link pending
kpti-ex10_2.htm Edgar Link pending
kpti-ex31_1.htm Edgar Link pending
kpti-ex31_2.htm Edgar Link pending
kpti-ex32_1.htm Edgar Link pending
kpti-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
kpti-20240331_htm.xml Edgar Link completed
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending